SCHEMBL14924022

SCHEMBL14924022

CCN1CCN(CC(=O)c2ccc(C(C)C)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
ALDH1A1 P00352 10/20 0.62
LMNA P02545 4/20 0.62
KDM4E B2RXH2 1/20 0.62
TP53 P04637 1/20 0.57
NSD2 O96028 1/20 0.54
MAPT P10636 1/20 0.50
GAA P10253 1/20 0.50
POLB P06746 2/20 0.49
USP5 P45974 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
ATM Q13315 1/20 0.46
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HTR2A P28223 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12074133 0.84 MEN1 (0.73) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL26078955 0.84 TP53 (0.54) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL12919996 0.83 TP53 (0.53) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL14924456 0.82 MEN1 (1.00) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL12545322 0.81 ALDH1A1 (0.72) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL26502340 0.76 TP53 (0.47) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL26501820 0.76 PANK3 (0.59) MEN1KMT2AALDH1A1KDM4ETP53
SCHEMBL15340905 0.74 KMT2A (0.64) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL19748976 0.74 PANK3 (0.66) TP53POLB
SCHEMBL3404341 0.74 USP5 (0.63) MEN1KMT2AALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 US disclosed
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2016-08-11 US disclosed
US-9345719-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2016-05-24 US disclosed
US-8957065-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD (KR) 2015-02-17 US disclosed
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2015-02-12 US disclosed
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD. (KR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, LTK, FYN MEN1 4259/4885KMT2A 1857/4885ALDH1A1 3955/4885
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 MEN1 3929/4885KMT2A 1823/4885ALDH1A1 3912/4885
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 MEN1 3929/4885KMT2A 1823/4885ALDH1A1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.